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Abstract.
Background: Cathepsin D (CatD) is a lysosomal protease that is elevated early in Alzheimer’s disease (AD). We have previously
developed a Targeted contrast agent (CA) to detect CatD activity in vivo, consisting of a magnetic resonance imaging/fluorescent
moiety linked to a cell penetrating peptide (CPP) by means of a CatD cleavage site and have demonstrated its uptake in the brain
of an AD mouse model.
Objective: The purpose of this study was to characterize the in vivo retention of a near infra-red fluorescent dye labeled version
of this CA.
Methods: Six adult C57Bl/6 wild-type mice and six adult 5XFAD transgenic AD mice were studied using a small animal
imaging system at five and twelve months of age using our novel Targeted CA, or two different control CAs; a Non-Targeted
(lacking the CatD cleavage site) and a Non-Penetrating (lacking the CPP). Following intravenous CA administration, the optical
signal was recorded within the brain and uptake and washout curves were measured and fitted to a one-phase exponential decay
curve.
Results: In all wild-type and 5XFAD mice, the washout of the Targeted CA that included a CPP domain was significantly
slower than the washout of the Non-Penetrating and Non-Targeted CA. Furthermore, the washout of the CatD Targeted CA was
significantly slower in the 5XFAD mice compared to the age matched wild-type controls (p < 0.05) at 5 and 12 months of age.
Control CAs showed no differences in washout.
Conclusions: The prolonged retention of the CatD targeted CA in 5XFAD mice suggests this agent may be useful for AD
detection.
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INTRODUCTION
An estimated 115 million people will have demen-
tia by 2050 worldwide with Alzheimer’s disease (AD)
being the most common cause [1]. The first description
of AD over a century ago highlighted neurofibrillary
ISSN 1387-2877/15/$35.00 © 2015 – IOS Press and the authors. All rights reserved
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tangle (NFT) and amyloid plaque accumulation [2] as
two pathological changes associated with the disease.
These have remained central to the postmortem con-
firmation and definitive diagnosis of AD to this day;
however, the development of AD involves many sub-
cellular and morphological features associated with
loss of synapses [3], mitochondrial dysfunction and
oxidative stress [4], and neurovasculature disruption
[5, 6]. Currently, diagnosis of AD is based upon clin-
ical assessment, and although biomarkers have been
proposed, these are not uniformly recommended for
clinical use. This problem has taken on urgency, as sev-
eral promising clinical trials may have failed, because
treatment was initiated too late in the disease, when
irreversible synaptic and neuronal loss had already
occurred [7–11].
The development of imaging biomarkers provides
a means to non-invasively detect brain changes asso-
ciated with AD to monitor disease progression and
the effects of treatment. Imaging biomarkers include
brain structural changes [12], blood flow [13, 14], func-
tion [15], and glucose utilization [16, 17]. Recently,
positron emission tomography (PET) imaging with
the 11C-labelled Pittsburgh compound B, or PiB [18]
has provided insight into the accumulation of amy-
loid pathology in the brain. PiB binding correlates with
cerebral atrophy [19], it inversely correlates with cere-
bral glucose metabolism [20], and it strongly relates
to the degree of memory impairment [21]. However,
some studies have also shown PiB uptake in a signifi-
cant proportion of non-demented elderly controls [22].
Moreover, many anti-amyloid treatments have failed in
clinical trials and therefore interest in NFT pathology
has intensified [23]. Imaging this biomarker, an aggre-
gate of hyperphosphorylated tau protein, could provide
important information about the course of the disease
[24]. Novel ligands targeting NFT have shown promise
in murine models of AD [25, 26] and more recently in
humans [27, 28]. Currently, however, the aforemen-
tioned biomarkers are hampered by variability and are
frequently positive in normal older patients [7, 23, 29]
sometimes more than 15 years before clinical symp-
toms [30].
One possible novel biomarker for AD is Cathepsin
D (CatD). CatD is a lysosomal aspartic endopepti-
dase (EC 3.4.23.5) involved in normal protein turnover
associated with tissue homeostasis including tissue
renewal, remodeling, and regulation of aging and pro-
grammed cell death [31]. However, CatD is elevated
within brain parenchyma and the cerebrospinal fluid
of AD patients and active CatD is present at high
levels in amyloid plaques [32–34]. In addition,
increased expression of CatD has been proposed to
be the earliest histopathological feature of AD [33].
Therefore, there is increasing interest in developing
molecular imaging techniques targeting CatD for the
early diagnosis of AD [35].
Animal models provide a consistent platform for
testing early diagnostic techniques and can provide
insight into the etiology and pathophysiology of human
neurodegenerative diseases [36]. Transgenic (Tg) mice
are the most common model of AD, while very few rat
[37], and even fewer non-human primate models exist
[37–39]. Although many different Tg mouse strains are
available, the 5XFAD model [40] has several key fea-
tures requisite for AD modeling. These mice rapidly
accumulate cerebral pathogenic amyloid protein (A)
that begins at two months and reaches a very large
burden by nine months. They are also characterized
by hippocampal synaptic dysfunction as early as six
months [41], and impaired memory as well as neu-
ronal loss and synaptic degeneration by nine months
that worsens by 12 months [40]. Furthermore, previ-
ous work using this strain showed co-localization of the
CatD enzyme with intra-lysosomal A aggregates at
one month of age [42] and increased CatD expression
compared to non-Tg controls at 3.5 months [43]. The
latter suggests that this strain is an appropriate plat-
form for investigating contrast agents (CA) targeting
CatD.
The passage of molecules from the circulation across
the blood-brain barrier (BBB) into the brain is highly
selective, making drug delivery difficult [44–47]. Most
CAs do not normally cross the BBB unless it is dam-
aged. One strategy to deliver contrast agents into the
brain is to use cell penetrating peptides (CPP) [48]. One
CPP is derived from Tat peptide (YGRKKRRQRRR)
of the HIV-1 virus, which allows transport both into
and out of the brain [48]. This CPP has been explored
for drug delivery [49] as well as cellular delivery of
CAs [50]. It is believed that hydrophilic arginine-rich
CPPs such as HIV-1 Tat may be transported across
membranes by direct penetration at high concentra-
tions [51], and by endocytosis at lower concentrations
[52], although there is no consensus on the mechanism
of uptake and maintenance of functionality of cargos
after delivery [53].
We have previously described a dual modality (MRI
and fluorescence) CatD targeted CA consisting of an
imaging moiety conjugated to a peptide composed of a
CatD cleavage site and a CPP [54, 55]. The CPP allows
transport across membranes bidirectionally. In regions
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with increased CatD activity, cleavage at the CatD site
removes the CPP, causing prolonged retention of the
imaging moiety. Because each CatD enzyme molecule
can cleave many substrate CA molecules, this strategy
potentially offers amplification compared to contrast
agents that depend on target binding. We have shown
that this CA is taken up preferentially by cultured cells
overexpressing CatD [54]. In addition, it exhibited a
distinct difference in uptake and retention over a 2 h
period post administration in an APPswe, PSEN1dE9
Tg mouse model compared to wild-type (WT) mice
in ex vivo studies [55]. In the current study, we have
conjugated this agent with IRDye 800, a near infra-
red (NIR) fluorescent dye that can be detected through
several centimeters of tissue [56] and exhibits a much
higher fluorescence than the commonly used NIR dye
indocyanine green [57]. This fluorophore has increased
stability in blood [58] and is non-toxic at doses up to
∼428 nmol [59]. As little as 5 pmol [58, 60] of this dye
is required for detection in rodents. This new agent
is suited for in vivo, non-invasive optical imaging to
examine CA washout kinetics following intravenous
administration.
The objective of this study was to evaluate the uptake
and washout kinetics of the newly modified CA in vivo
in 5XFAD Tg AD and WT control mice using NIR opti-
cal imaging. We hypothesized that the agent would be
preferentially retained in the brain of 5XFAD Tg mice
compared to WT mice. To better understand the mech-
anism of uptake of this agent, we compared washout
kinetics for three similar CAs in 12-month-old 5XFAD
and WT mice: 1) a diagnostic CatD Targeted agent hav-
ing an imaging moiety, a CatD cleavage site, and a CPP;
2) a control Non-Penetrating agent having an imaging
moiety, an incomplete CatD cleavage site lacking the
CPP; and 3) a control Non-Targeted agent having only
an imaging moiety and a CPP but no CatD cleavage
site. Here we show that the cell penetrating CatD Tar-
geted CA is taken up and retained more efficiently in
the brain than the Non-Penetrating and Non-Targeted
agents, and that this agent can distinguish AD mice
from WT mice at 5 months and 12 months of age.
MATERIALS AND METHODS
CA synthesis and characterization
The IRDye 800 from LI-COR Biosciences (Lin-
coln, NE, USA) was chosen for NIR detection (part
of the detection probe along with the chelated Gd3+
lanthanide metal). Peptide sequences were assem-
bled on a Wang resin using a standard solid phase
peptide synthesis protocol [63]. Conjugation of DOTA-
derived terminal monomer and subsequent HPLC
purification of peptides 1a-c was performed as pre-
viously described [54, 55] (Fig. 1). In separate
reaction vessels (Falcon tubes) peptides 1a (4.2 mg,
1.2 × 10–6 mol), 1b (0.7 mg, 3.0 × 10–7 mol), and
1c (2.7 mg, 1.5 × 10–6 mol) were treated with the
solution of IRDye 800CW maleimide (2; 1.4 mg,
1.2 × 10–6 mol, peptide 1a; 0.4 mg, 3.0 × 10–7 mol,
peptide 1b; 1.8 mg, 1.5 × 10–6 mol, peptide 1c) in
acetonitrile (200 L, peptide 1a; 100 L, peptide 1b;
400 L, peptide 1c) and water (1 mL, peptide 1a;
400 L, peptide 1b; 1.6 mL, peptide 1c). The tubes
were set aside for 48 h at room temperature in the
dark (wrapped in Al foil). The solvents were removed
by lyophilization, the residues were dissolved in
acetonitrile (200 L, peptide 1a; 50 L, peptide 1b;
300 L, peptide 1c) and water (1 mL, peptide 1a;
100 L, peptide 1b; 300 L, peptide 1c) and 0.1 M
solution of GdCl3 · 6H2O (38 L, 3.8 × 10–6 mol,
peptide 1a; 10 L, 1.0 × 10–6 mol, peptide 1b; 30 L,
3.0 × 10–6 mol, peptide 1c) was added. The tubes were
set aside for another 48 h at room temperature in the
dark (wrapped in Al foil). The solvents were removed
by lyophilization, the residues were dissolved in water
and were purified by dialysis (for 5 days) using a
membrane with a molecular weight cut-off of 500 Da.
The solutions were lyophilized to produce the desired
peptides 3a-c as green solids. The conjugates were
characterized by high resolution electrospray ionisa-
tion mass spectroscopy (HR-ESI-MS) as follows:
Conjugate 3a (1.9 mg, 35%), HRMS (ESI) m/z:
found 4512.0560 [M-2H]+ (4512.0456 calculated for
C194H299N56O49S5Gd).
Conjugate 3b (0.9 mg, 90%), HRMS (ESI) m/z:
found 3387.3570 [M-2H]+ (3387.3615 calculated for
C137H210N42O39S5Gd).
Conjugate 3c (4.2 mg, 78%), HRMS (ESI) m/z:
found 2584.8555 (formic acid adduct) [M-2H]+
(2584.8543 calculated for C110H152N18O34S5Gd).
The three conjugates were named according to their
functional characteristics: Conjugate 3a (Fig. 1) was
dubbed the CatD Targeted or diagnostic CA (hav-
ing a CatD cleavage site and a CPP), conjugate 3b
(Fig. 1) was dubbed the Non-Targeted CA (having only
a CPP), and conjugate 3c (Fig. 1) was dubbed the Non-
Penetrating CA (having only a partial CatD cleavage
site, similar to what remains following cleavage by an
active CatD enzyme).
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Fig. 1. Synthesis of the different CAs. CatD Targeted (3a), Non-Targeted (3b), and Non-Penetrating (3c) conjugates used in this study.
CA optical properties
Optical properties were characterized using a Spec-
traMax M5 spectorphotometer plate reader (Molecular
Dynamics Devices, Sunnyvale, CA, USA). The opti-
mal excitation wavelength of our CA was determined
for emission at 845 nm using excitation between 600
to 820 nm (no cut-off filter, high precision reading,
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and 2 nm step size). The optimal emission wave-
length was made at wavelengths ranging from 790
to 850 nm following excitation at 780 nm. To control
for backscatter and lamp light contamination, the puri-
fied milli-Q water fluorescence values were subtracted
from all other measurements. Furthermore, to measure
CA fluorescence following cleavage with the targeted
enzyme (C3138-10UN; Sigma-Aldrich Canada Co.,
Oakville, Ontario), 25 M solutions of either CatD
targeted, non-penetrating, or non-targeted CA were
maintained at 37◦C and a low pH (∼4.5) to repli-
cate in vivo lysosomal conditions. Six wells were
used to test each CatD targeted CA but three wells
also included the CatD enzyme (0.7 M) incubated
with the CA for ∼30 min. Additionally, the fluorescent
signal from each sample was measured as a func-
tion of time using the eXplore Optix system (GE
Healthcare, Milwaukee, WI, USA). The fluorescence
signal was examined in both the eXplore Optix sys-
tem and the SpectraMax M5 Molecular Devices plate
reader by measuring the signal from 1.35, 2.75, 5.5,
and 11 M concentrations of the CA corresponding
to 0.27, 0.55, 1.1, and 2.2 nmol, respectively. These
solutions were placed in a black solid Costar 96-
well plate (Corning Life Science, Tewksbury, MA,
USA).
Animals
All animal studies were conducted in accordance
with the guidelines of the Subcommittee on Animal
Care at Western University, conformed to the Canadian
Council on Animal Care guide for the care and use of
laboratory animals as well as the ARRIVE guidelines.
B6SJL-Tg (APPSwFlLon, PSEN1∗M146L∗L286V)
6799 Vas/Mmjax Tg mice, commonly known as the
5XFAD line Tg6799 of a C57Bl/6 and B6SJL hybrid
background and age-matched WT C57Bl/6 (both
from Jackson Laboratories, Bar Harbor, ME, USA)
were used for this study. The 5XFAD mice overex-
press human APP (695) with the Swedish (K670N,
M671L), Florida (I716V), and London (V717I) Famil-
ial Alzheimer’s Disease (FAD) mutations and the
human PS1 gene harboring two FAD mutations,
namely, M146L and L286V [43].
There was no significant difference in aver-
age mouse weight (5XFAD: 23.1 ± 1.6 g; WT:
23.5 ± 2.5 g) between the groups at five months; how-
ever, at 12 months, the body weight of the 5XFAD mice
(23 ± 1.5 g) was significantly lower (p < 0.05) than the
WT mice (31 ± 1.9 g).
Experimental design
To examine whether the CatD Targeted diagnostic
CA could be used to differentiate between old 5XFAD
mice having progressive disease pathology and old
yet healthy control mice, six (n = 6) 5XFAD and six
(n = 6) age-matched WT (C57Bl/6) control mice were
studied at 12 months of age. To determine whether
observed differences could be attributed to the target-
ing and BBB penetrating moieties attached to the CA,
the uptake and washout of the three different CA ver-
sions were compared. The ability of the CatD Targeted
CA to differentiate between the 5XFAD and WT con-
trol mice at an earlier disease stage was also studied at
five months of age.
Optical imaging
Animals were kept warm (∼37◦C) using a latex
glove containing warm water placed over the lower
back and extremities. The warm water was replaced
every 10 min. Two animals were scanned simulta-
neously using a Y-shape nose cone for isofluorane
anesthesia with a scavenger system connected to a
charcoal filter. Hair was removed from the scalp using
an electric razor, and depilatory agent (e.g., Nair;
Brookvale, Australia) prior to optical imaging. All
mice received an intravenous injection of 5 nmol CA
suspended in 200 L PBS through a tail catheter. One
(n = 1) 5-month-old 5XFAD mouse received a subcu-
taneous (sc) injection in the flank to examine the time
delay for peak fluorescent signal.
Optical imaging was performed using the eXplore
Optix system (GE Healthcare, Milwaukee, WI, USA);
a reflectance-based, raster scanning, time domain opti-
cal imaging system with a 3 mm source–detector
distance. An 80 MHz, 780 nm pulsed diode laser (pico-
Quant, Berlin, Germany) was employed with a 10 nm
FWHM bandpass excitation filter centered at 780 nm
(Thorlabs, Newton, NJ, USA). Light was collected
with a 55 nm FWHM bandpass excitation filter cen-
tered at 845 nm (Chroma Technology Corp., Bellows
Falls, VT, USA). The maximum power output of the
laser at the surface of the sample or animal did not
exceed 10 W, and signal was collected with an inte-
gration time of 100 ms resulting in an image acquisition
time of ∼2 min. Images were acquired for a maximum
duration of 4.5 h (270 min), with a variable temporal
step size depending on the magnitude of the observed
signal changes. The horizontal level of heads of both
animals was manually adjusted to be of equal distance
to the detector.
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Optical signal analysis
All optical signal data were recorded as photon
counts per second for each pixel. Optical signal maps
were analyzed using ImageJ 1.46r (National Institutes
of Health, USA). Statistical analysis was performed
using Prism 5 (GraphPad Software, Inc., CA, USA).
The average fluorescence signal (average pixel inten-
sity ± standard deviation) time course from within a
selected region of interest (ROI) was used for analysis.
Unless otherwise stated, the ROI was drawn around
only the head region visualized under plain white light
(WL). The baseline signal amplitude was centered at
zero by subtracting the background signal measured
prior to the injection of agent. To equalize the step
sizes, a piecewise cubic Hermite interpolation was
applied to the data and binned into 1-min intervals
using MATLAB (The MathWorks, Inc., Natick, MA,
USA). For all parameters excluding the absolute peak
enhancement values, the CA signal was normalized
to the maximum intensity. The CA washout following
maximum peak enhancement was modeled and fitted
using a least squares minimization method in Prism.
The model function incorporated a constant maximum
enhancement period followed by a one phase exponen-
tial decay [Eq 1] to determine the washout coefficient
(λTotal) and asymptote (Plateau Total ).
Y (t) =
⎧⎪⎨
⎪⎩
Y0, t < T0
PlateauTotal + (Y0 − PlateauTotal)
e−λTotal(t−T0), t ≥ T0
(1)
The initial values of Y0 (Y-intercept) were set to
1 because the data were normalized. T0, the time
delay from CA administration to washout was fitted
by Prism to account for variability in the start time of
observed CA washout, and the asymptote PlateauTotal
was restricted to values greater than zero. The lat-
ter constraint is reasonable because the CA will not
clear from the body completely within the scan time
allotted for the current study, however, we observed
the signal return to baseline levels (n = 2) within 24 h;
data not shown. For statistical purposes, the extra
sum-of-squares F-test was used to compare the param-
eters λTotal and PlateauTotal between groups with a
p-value <0.05 required to achieve significance.
The time delay following maximum enhance-
ment to signal washout (T0), the absolute maximum
peak signal intensity value (SImax ), the linear slope
(SI2hrs–SI1hrs ) between the signal at 1 h post injec-
tion (SI1 ) and the signal at 2 h (SI2 ) post injection,
and the attenuation coefficient for data collected dur-
ing the first hour post peak enhancement (λ1hr )
assuming a plateau of zero were measured in each ani-
mal. Both SI2hrs–SI1hrs and λ1hr were calculated to
provide a straight-forward metric that could be eas-
ily applied in patients. A Student’s t-test was used
to compare parameters between the different groups
with a p-value <0.05 required to achieve significance.
Receiver Operating Characteristic (ROC) curve anal-
ysis was performed using the Prism built-in analysis
tool with 95% confidence level to determine whether
CA washout parameters (T0, λ1hr , and SImax ) could
differentiate between the AD model to WT control
mice.
CatD expression in brain tissue
WT and 5XFAD mice (4 and 12 months old)
were perfused with saline followed by 10% neutral
buffered formalin (NBF). Brains were dissected and
immersed in 10% NBF for 24 h, embedded in paraf-
fin, and 5 m sections were cut. Antigen retrieval
was performed using formic acid (70%, 2 min) and
sections were immunolabeled with antibody against
CatD (1 : 200; C-20 sc-6486 from Santa Cruz Biotech-
nology; Santa Cruz, CA, USA). This antibody was
detected using an anti-rabbit secondary antibody con-
jugated to horseradish peroxidase, prior to colorimetric
detection using nickel 3,3′-diaminobenzidine (DAB;
0.15 mg/ml in 0.03% H2O2; Sigma-Aldrich, Oakville,
ON, Canada) with the Vectastain ABC kit (Dako,
Burlington, ON, Canada) and counterstaining with
Hematoxylin and Eosin (H&E; Leica Microsystems
Inc., Concord, ON, Canada). Sections were imaged
and digitized using a TISSUEscope CF slide scan-
ner (Huron Technologies, Waterloo, ON, Canada) at
a 0.5 m resolution using bright field imaging (at
40X). Staining area was measured in three regions
(each covering >200,000 m2) of primary somatosen-
sory cortex in each of three sections per mouse, in
each of three mice per group using ImageJ (v. 1.46r,
http://rsbweb.nih.gov/ij/) with staining identified using
the color deconvolution plugin written by Dr. Gabriel
Landini (available via the aforementioned website) and
quantified using the ImageJ built-in threshold tool.
RESULTS
CA optical properties
Measuring the fluorescence at 845 nm, each CA
had an excitation peak at 780 nm (similar to non-
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C D
Fig. 2. Fluorescence characteristics of the CAs. A) Emission spectrum observed using the M5 plate reader at different wavelengths following
excitation at 780 nm for the CatD Targeted CA (blue upside down triangles), the Non-Penetrating CA (green circles), and the CatD Targeted
CA incubated with CatD (red triangles). The CatD Targeted agent has a peak width of about 15 nm (FWHM) centered at ∼805 nm, whereas
the Non-Penetrating agent has a peak emission centered below 790 nm (Not shown). B) Fluorescence characteristics of the CatD Targeted CA
interaction with a CatD enzyme using the GE Optix eXplore optical scanner. The fluorescent signal intensity, normalized to the signal intensity
prior to enzyme addition (0.7 M), increases to ∼1.5 times the baseline level 1 h after incubation with the enzyme at 37◦C. The fluorescence
measurements by both (C) M5 plate reader (red) and (D) eXplore optix (blue) for the same concentrations of CatD targeted CA in PBS are
shown where regression lines for each set are plotted.
conjugated IRDye 800). We then measured the
emission intensity spectrum for all three CA variants
using an excitation laser at 780 nm. The CatD Targeted
(Fig. 2A, upside down blue triangles) and Non-
Targeted (data not shown) agents had a similar peak
emission centered at ∼805 nm. The Non-Penetrating
CA (Fig. 2A, green circles), lacking the CPP, produced
a higher peak at a slightly lower wavelength, which
could not be fully measured because it overlapped
with the excitation light source. The CatD Targeted CA
incubated with the CatD enzyme (Fig. 2A, red trian-
gles) produced an intermediate curve with significantly
higher fluorescence than the intact, CatD Targeted
CA at wavelengths below 800 nm. Furthermore, the
Optix eXplore pre-clinical scanner measurements of
the CatD Targeted CA after CatD enzyme addition
showed a gradual increase in fluorescence over time,
to about 1.5 times the original signal (Fig. 2B).
The optical fluorescent signal changes detected using
the M5 plate reader (Fig. 2C) were linear with CA
concentration (ex/em 780/845 nm; R2 = 0.986) and
correlated strongly (Pearson correlation R2 = 0.97;
p = 0.01) with the optical signal measured using
the Optix eXplore pre-clinical scanner measurements
(Fig. 2D) which were similarly linear with CA concen-
tration (R2 = 0.997).
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Fig. 3. Uptake and washout of the CatD targeted CA in a 5XFAD
mouse. The NIR signal is collected over time from an ROI (white
outline in A) with associated pseudo color bar indicating pho-
tons/second (A). The brain signal is then analyzed from an elliptical
ROI (red outline in A; red data in B) drawn over the brain region and
a control region closer to the neck (green outline in A; green data
in B). Representative images of signal intensity are shown (left to
right; I to IV) that correspond to epochs designated by the assigned
letters on the NIR intensity curve (B). Analyzed variables include
(some are indicated in B): the time delay from CA administration
to washout (T0 ), the peak signal intensity (SImax ), the exponential
signal decay coefficient for the duration of each scan (λTotal), the sig-
nal value at asymptote (plateauTotal ), the exponential signal decay
coefficient for 1 h washout (λ1hr), the signal intensity at 1 h and 2 h
after injection (SI1and SI2 respectively) and their associated signal
decay rate (SI2hrs –SI1hrs ).
Optical signal dynamics
An example of the NIR imaging data acquired on the
GE eXplore Optix scanner is shown in Fig. 3. Follow-
ing injection of the contrast agent, signal was acquired
from the head (Fig. 3A; white rectangular ROI) to
produce images. Signal changes from ROIs over the
brain (Fig. 3A; red elliptical ROI) and from the skin
and soft tissue over the neck (Fig. 3A; green ROI)
were examined. Generally, optical signal increased
rapidly following injection, reached a peak value, and
then declined over time; a typical curve is shown in
Fig. 3B. The signal from the skin/neck was more than
10-fold lower than the signal from the brain region.
More importantly, there were no significant differences
observed in the uptake/washout kinetics of the CatD
targeted CA between 5XFAD and WT mice in the
skin/neck region (data not shown), therefore all sub-
sequent analysis focus on the signal measured from
the brain region only.
The key features of the uptake and washout curve
include the time delay to signal washout (T0 ), the peak
signal intensity (SImax ), the exponential signal decay
coefficient for the entire scan period (λTotal ) or 1 h
washout (λ1hr ) starting at peak value, the asymptotic
signal (PlateauTotal ), and lastly, the linear slope
(SI2hrs–SI1hrs ) between the signal measured at 1 h
and 2 h post injection. The measured characteristics
of these curves are summarized in Table 1 for the
12-month-old mice and in Table 2 for the 5-month-old
mice.
Contrast agent pharmacokinetics in 12-month-old
mice
The pharmacokinetics of the different contrast
agents were compared in 12-month-old WT mice
(Fig. 4; Table 1). As expected, the signal from the
Non-Penetrating CA (green curve, Fig. 4) peaked very
quickly following injection (T0 = 14.1 ± 2.3 min; λ1hr
= –1.42 ± 0.14 × 10–2 min–1). The Non-Targeted
CA (orange curve, Fig. 4) had a slightly longer
T0 (18.9 ± 3.5 min) with a 10% increase in sig-
nal at peak compared to initial measurements, and
washed out more slowly (λ1hr = –1.25 ± 0.2 × 10–2
min–1). Finally the CatD Targeted CA (blue curve,
Fig. 4) exhibited the longest time delay to peak (T0 =
46.5 ± 8.2 min), and was cleared much more slowly
(λ1hr = –0.52 ± 0.03 × 10–2 min–1) than the control
CAs demonstrating the prolonged retention of the
Targeted agent requires both the CPP and the CatD
cleavage site.
The uptake and washout curves for each contrast
agent were compared between 12-month-old WT and
5XFAD mice in Fig. 5, and the analysis of five
different features is summarized for all groups in
Table 1. Following injection of the Targeted CA, the
uptake and washout curves of the 5XFAD and WT
animals are clearly separated throughout the exper-
iment (Fig. 5A). Although the CatD Targeted agent
shows a trend to take longer to reach maximum
signal intensity in 5XFAD mice (72.2 ± 43.8 min)
compared to controls (46.5 ± 8.2 min), this difference
was not statistically significant. The CatD Targeted
agent reached a higher SImax in the 5XFAD mice
(7.1 ± 0.8 × 103 photons/s, Fig. 5A) compared to the
WT mice (4.6 ± 0.5 × 103 photons/s; p = 0.019). The
CatD Targeted agent washout coefficient fitted at 1 h
(λ1hr ) for 5XFAD mice (–0.28 ± 0.08 × 10–2 min–1)
was significantly different than for the WT con-
trols (–0.52 ± 0.03 × 10–2 min–1; p < 0.05, Fig. 5B,
Table 1) as was the washout parameter λTotal
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Fig. 4. CA mechanistic uptake and washout. Average optical imag-
ing signal measurements for 12-month-old WT mice injected with
either the Non-Penetrating CA, Non-Targeted CA, or CatD Tar-
geted CA. Data were normalized to the first post CA administration
measurement (mean ± SEM).
(–3.68 ± 0.20 versus –0.68 ± 0.03 for 5XFAD and
control respectively; p < 0.01, Fig. 5B, Table 1). In
addition, the asymptote (PlateauTotal ) was almost four
times higher in the 5XFAD mice (82 ± 1%) compared
to the control mice (23 ± 2 %, p < 0.01). Finally, there
was a significant difference between SI2hrs –SI1hrs
(–0.43 ± 0.02 versus –0.15 ± 0.08 for 5XFAD and
control mice respectively (Table 1, p < 0.01) in 5XFAD
mice and WT controls. Taken together, these results
indicate that the contrast agent reached a significantly
higher plateau in the 5XFAD mice compared to the
WT mice and reached it faster.
To test whether the CatD targeted CA could differ-
entiate between 5XFAD and WT mice, a ROC analysis
was performed incorporating three different param-
eters (T0 , λ1hr , and SImax ) (null hypothesis: true
area = 0.5). For the 12-month-old 5XFAD compared
to WT mice, the area under the curve (AUC) was
0.78 (p = 0.11), 0.81 (p = 0.07), and 0.86 (p = 0.04), for
T0 , λ1hr and SImax , respectively.
Non-Targeted and Non-Penetrating agents in
12-month-old mice
When WT mice were injected with the Non-
Targeted CA, it took significantly longer for the signal
to reach peak enhancement (T0 ) compared to the
5XFAD mice (Table 1, p < 0.01). However, there was
no difference between groups in the time to peak for
the Non-Penetrating agent. Most importantly, there
were no significant differences between the parameters
λTotal , plateauTotal , and λ1hr when comparing the
5XFAD and WT mice after administration of either the
Non-Targeted (Fig. 5C) or Non-Penetrating (Fig. 5D)
CAs (Table 1).
Table 1
Fluorescent signal intensity curve characteristics (average ± standard error; n = 6) in 12 months old 5XFAD and wild-type (WT) mice following
different contrast agent (CA) injections
WT 5XFAD
Curve Characteristic Non-Penetrating Non-Targeted Cathepsin D Targeted Non-Penetrating Non-Targeted Cathepsin D Targeted
T0 (min) 14.1 ± 2.3 18.9 ± 3.5§§ 46.5 ± 8.2 §§ 11.4 ± 2.8 9.8 ± 4.1∗ 72.2 ± 43.8 §§
λ1hr (×10–2 min–1) –1.42 ± 0.15 –1.25 ± 0.18 –0.52 ± 0.03§§ –1.42 ± 0.13 –1.28 ± 0.20 –0.28 ± 0.08 *§§
λTotal (×10–2 min–1) –1.48 ± 0.03 –1.15 ± 0.07§ –0.68 ± 0.03 §§ –1.33 ± 0.27 –1.23 ± 0.45 –3.68 ± 0.20 **§§
PlateauTotal (%) 0 ± 2 0 ± 3 23 ± 2 §§ 1 ± 1 0 82 ± 1 ** §§
SI2hrs –SI1 hrs (×10–2 min–1) –0.43 ± 0.02 –0.15 ± 0.08 ∗∗
∗Significantly different from WT group (same CA) p ≤ 0.05; ∗∗p ≤ 0.01. §Significantly different from non-penetrating CA (same strain) p ≤ 0.05;
§§p ≤ 0.01. Significantly different from non-targeted CA (same strain) p ≤ 0.05; p ≤ 0.01. n = 2.
Table 2
Fluorescent signal intensity curve characteristics (average ± standard error; n = 6) in 5 months old 5XFAD and wild-type (WT) mice following
injections of the Cathepsin D targeted contrast agent (CA)
Curve Characteristic WT 5XFAD
Cathepsin D Targeted Cathepsin D Targeted
T0 (min) 39.2 ± 28.8 64.1 ± 25.8
λ1hr (×10–2 min–1) –0.92 ± 0.08 –0.62 ± 0.08 ∗
λTotal (×10–2 min–1) –1.25 ± 0.03 –1.02 ± 0.06 ∗∗
PlateauTotal (%) 24 ± 1 27 ± 2
SI2hrs –SI1 hrs (×10–2 min–1) –0.48 ± 0.08 –0.35 ± 0.08
∗Significantly different from WT group (using CatD Targeted CA) p ≤ 0.05; ∗∗p ≤ 0.01.
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A B
C D
Fig. 5. Uptake and washout in 12-month-old WT and 5XFAD mice following CA administration. Non-normalized data for twelve month old
mice injected with CatD Targeted CA (A; 5XFAD in red, WT in blue), normalized shifted data for 12-month-old mice injected with CatD
Targeted CA (B; 5XFAD in red, WT in blue), mice injected with Non-Targeted CA (C; 5XFAD in red, WT in blue), and mice injected with
Non-Penetrating CA (D; 5XFAD in red, WT in blue) are shown. Data are the mean ± standard error of fluorescent signal as a function of time
(n = 6).
A B
Fig. 6. CA washout in 5-month-old WT and 5XFAD mice following CatD Targeted CA administration. Non-normalized data for 5-month-old
mice injected with CatD Targeted CA (A; 5XFAD in red, WT in blue, n = 5), normalized shifted data for 12-month-old mice injected with CatD
Targeted CA (B; 5XFAD in red, WT in blue, n = 6), data shown is mean ± standard error of fluorescent signal as a function of time.
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Fig. 7. Immunohistochemistry of CatD in WT and 5XFAD mice at 4 and 12 months of age. Photomicrographs of the cortex in mice showing
CatD staining (brown) with Hematoxylin counter staining of the nuclei (blue). Enlarged views (×2) show the vicinity near the black framed
rectangles. CatD staining is present intracellularly (e.g., arrow heads) and in amyloid plaques (e.g., arrows). Scale bar 100 m.
Fig. 8. Quantification of CatD-specific DAB staining. The area cov-
ered by CatD staining shown in Fig. 7 was quantitated using ImageJ
software (mean ± standard error of the mean; n = 3). Significant dif-
ferences are noted with an asterisk for p ≤ 0.01.
Contrast agent pharmacokinetics in 5-month-old
mice
The uptake and washout of the CatD Targeted CA
is shown in both 5-month-old 5XFAD and WT mice
in Fig. 6 and the average fitted curve parameter values
are provided in Table 2. Although there was a trend
for the T0 to be prolonged in the 5XFAD mice ver-
sus control mice (64.1 ± 25.8 versus 39.2 ± 28.8 min),
this difference was not significant. As with 12-month-
old mice, the clearance of the CatD Targeted agent at
1 h (λ1hr ) was significantly slower in 5XFAD mice
compared to WT mice (–0.62 ± 0.08 × 10–2 min–1
versus –0.92 ± 0.08 × 10–2 min –1; p < 0.05) as was
the overall clearance rate (λTotal ) (–1.02 ± 0.06 ver-
sus –1.25 ± 0.03 × 10–2 min−1; p < 0.05). However,
the PlateauTotal , and SI2hrs–SI1hrs were not different
between groups. The AUC for the ROC was evaluated
for λ1hr (null hypothesis: true area = 0.5). For the 5-
month-old 5XFAD compared to WT mice, the AUC
was significantly higher than the null hypothesis (0.89;
p = 0.02) for λ1hr, demonstrating that this agent can
successfully differentiate between WT and 5XFAD
mice at 5 months of age.
CatD expression
CatD expression was examined in primary
somatosensory cortex of WT and 5XFAD mice at 4
and 12 months of age using histology. Representative
tissue sections are shown in Fig. 7. In these sections,
CatD staining was visible intracellularly in WT
mice at 4 months of age, and staining increased at
12 months of age. The 5XFAD mice also showed
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intracellular CatD staining at both time points (Fig. 7;
arrow heads) but also demonstrated CatD staining
in large extracellular deposits resembling amyloid
plaques at both ages (Fig. 7; arrows). In these
sections, there appeared to be an increase in CatD
staining in 5XFAD mice compared to WT controls at
both ages.
The expression of CatD in these sections was
quantified by measuring the area covered by CatD
immunostaining using ImageJ (Fig. 8). At 4 months
of age, CatD staining covered 3.2 ± 0.3% of the cor-
tex in WT mice, and this increased to 16.2 ± 1.2% in
the 5XFAD mice (p < 0.01). Similarly, at 12 months of
age, CatD staining covered 5.8 ± 1.1% of the cortex
in WT mice, which increased to 29.5 ± 1.2% in the
5XFAD mice (p < 0.01). Staining was increased with
age in the 5XFAD mice (p < 0.01) but not in WT con-
trols. These results demonstrate that CatD expression
is increased in 5XFAD mice, and that this difference
increases with age.
DISCUSSION
Here, we characterize the behavior of a novel con-
trast agent targeting CatD for the diagnosis of AD
in the 5XFAD Tg Alzheimer mouse model. The CA
was composed of an MR/optical detection probe that
incorporated a chelated lanthanide metal (Gd) and a
NIR dye. The chelating DOTA structure allows clin-
ically translatable tomographic imaging modalities to
be pursued at a later time point (e.g., PET or MRI)
without the need for any chemical structural changes
[55]. The NIR dye was conjugated to a known and
validated [54] enzymatic hydrolysis site for CatD and
a cell penetrating Tat peptide. The Tat peptide allows
the agent to permeate the BBB and enter the brain in
a bidirectional fashion [48]. The Tat peptide has pre-
viously been shown to enter into the hippocampus and
portions of the cortex (known sites of heightened AD
pathology) with at least 0.2% of the intravenous dose
taken up per gram of brain [48]. Once inside the brain,
the cleavage at the CatD site removes the Tat peptide.
This enables the diffusion of the Tat peptide out of the
cell [54] while temporarily trapping the CA in the CNS
compartment.
Comparing the uptake and washout between the 12-
month-old 5XFAD mice and WT controls, the CatD
Targeted agent demonstrated clearly different uptake
and washout kinetics, with a higher SImax, a slower
washout (λ1hr , λTotal , and SI1hr–SI2h ) and a higher
plateau. In the 5-month-old mice, the cell penetrating
CatD Targeted CA exhibited a significantly lower rate
of clearance (λ1hr , SI1hr–SI2hr ) from the brain com-
pared to age-matched WT control mice resulting in
higher CA retention.
These results are consistent with our previous ex vivo
examination [55] of the uptake and washout of a simi-
lar CatD Targeted CA in 12-month-old APP/PS1-dE9
(APP/PS1) mice. The previous study also demon-
strated greater retention of the cell penetrating CatD
Targeted agent in APP/PS1 mice compared to WT mice
[55]. In the current study we were able to provide a
more complete in vivo evaluation of the CA washout
kinetics with the inclusion of Non-Targeted and Non-
Penetrating control agents. In the current study, no
differences in CA washout between 5XFAD and WT
animals were observed when using the control CAs,
suggesting that both the Tat peptide and the CatD cleav-
age site were required for the uptake and specificity of
the agent. Additional control experiments with use of
inhibitors targeting CatD activity would have helped to
prove the specificity of the cell penetrating CatD Tar-
geted CA. But we are unaware of inhibitors that have
the required kinetics and ability to cross through the
BBB.
The 5XFAD mice also exhibited a significantly
(p < 0.05) higher SImax compared to the WT control
mice following administration of the Non-Penetrating
CA (∼35% higher signal in 5XFAD), Non-Targeted
CA (∼64% higher signal in 5XFAD), and CatD-
Targeted CA (∼55% higher signal in 5XFAD). The
significantly higher SImax of the 5XFAD compared to
the WT mice coincided with a significant 26% lower
body weight (p < 0.05). Since the CA dose remained
at 5 nmol/injection regardless of weight, the SImax
was likely higher in the 5XFAD mice as a result of
an average 35% higher CA plasma concentration. The
fact that the Targeted and Non-Targeted agents had
SImax that averaged 64% and 55% higher, respectively,
implies increased uptake of the agents, and not merely
increased plasma concentration.
Another possible source of increased signal in the
5XFAD mice is the change in structure of the contrast
agent itself after interaction with CatD. For example,
the Non-Penetrating CA produced a higher emission
intensity at a shorter wavelength compared to the CatD
Targeted CA, while cleavage of the CatD Targeted
CA by CatD produced an emission spectrum that was
intermediate (Fig. 2A; red) as expected. The increased
fluorescence of the cleaved agent compared to the
intact CatD Targeted CA is likely due to quenching
of the fluorophore by the longer amino acid peptide
backbone in the CatD Targeted CA. As a result, enzy-
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matic cleavage of the CA could have contributed to
the significant increase in fluorescence intensity in the
5XFAD mice compared to WT controls.
There are several limitations that must be consid-
ered in the current study. The first is that we did not
asses the stability of the CA. However, the serum-based
half-lives of the CPP and IRDye 800CW are ∼8.8 h
[63] and ∼8 days [63], respectively, so, it is unlikely
that these components would degrade significantly in
the 4-h post-injection window studied here. We must
also consider the mouse models studied. Although
5XFAD mice only recapitulate some aspects of the
pathology observed in humans, this study used the
5XFAD because this model is known to have higher
levels of CatD compared to controls [42, 43], as is
the case in humans [32, 34]. Whether CatD overex-
pression precedes amyloid pathology in 5XFAD mice
similar to human AD pathology [33] has yet to be
shown; however, it is not a necessity for the prelimi-
nary investigation of our CA. In addition, we used WT
C57Bl/6 mice as the control group. Non-Tg littermates
would be preferred as they are a better genetic match
to the experimental group, and further studies compar-
ing Tg to non-Tg littermates are ongoing. Moreover,
although cerebral perfusion and vascular permeabil-
ity were not measured in these animals, the lack of
a significant difference in the washout kinetics of the
Non-Targeted and Non-Penetrating CAs between WT
and 5XFAD mice suggests that these factors were not
significantly different between these groups. Finally,
due to the nature of the non-tomographic optical
imaging used, the exact contribution of the CA accu-
mulated within the brain, skull, vasculature, and skin to
the detected signal is unknown. However, there were
no significant differences in the skin signal kinetics
between the 5XFAD and WT animals when using the
CatD targeted CA, no significant differences between
the 5XFAD and WT animals when using the con-
trol CAs, and CatD overexpression in the brain of
5XFAD mice was validated. Therefore, we believe that
the significant differences in observed signal kinetics
between the 5XFAD and WT animals are pre dom-
inantly the result of preferential brain uptake in the
5XFAD mice. Future utilization of tomographic imag-
ing techniques will provide further insight in to the
brain-specific accumulation of the CA compared to
other tissues.
The major strengths of this study are the use of
the engineered control CAs and the use of a NIR
dye. The use of agents lacking a CPP or CatD cleav-
age site demonstrate that the uptake and retention of
the CA are not non-specific, and depend on the CPP
and the CatD cleavage. Although complicated light
scattering of the NIR signal reduces resolution com-
pared to Oregon Green fluorescence in our previous
work, the NIR signal provides much higher signal-to-
background contrast, and reduced auto-fluorescence.
Furthermore, because NIR light can penetrate tissues
for up to several centimeters, it allows imaging of the
agents in live animals.
In conclusion, we have developed a contrast agent
that targets CatD and shows promise as a tool for the
diagnosis of AD. Specifically, the measured λ1hr as
well as λTotal with its associated PlateauTotal fol-
lowing administration of the cell-penetrating CatD
Targeted CA may be used to differentiate between
AD model mice and WT controls at 5 months and 12
months of age. At 12 months of age, SI1hr–SI2hr and
PlateauTotal may also be used to differentiate between
AD and WT mouse models. This study is the first to
provide proof of principle for in vivo detection of AD in
an animal model with CatD overexpression, a unique
yet validated human pathology associated with AD.
Future studies will examine CatD expression over the
lifespan of several animal models and correlate these
findings with the development of AD pathology.
ACKNOWLEDGMENTS
The authors gratefully acknowledge student stipend
support donated by William Shipman and from the
Alzheimer Society of London and Middlesex, the
Queen Elizabeth II Graduate Scholarships in Science
and Technology, and the Ontario Graduate Scholar-
ships. Additionally, the authors express much gratitude
to the Lawson Health Research Institute optical imag-
ing lab, Jennifer Hadway and Lise Desjardins (both
RVT, RLAT-R) for their experimental and animal
handling support, Dr. Mamadou Diop for hardware
technical support, and finally Zengxaun Nong and
Caroline O’Neil for histology and staining expertise.
Additionally, funding for this study was provided by
the Canadian Institutes of Health Research (MOP-
106535).
Authors’ disclosures available online (http://j-
alz.com/manuscript-disclosures/15-0123r1).
REFERENCES
[1] Alzheimer’s Association (2014) 2014 Alzheimer’s disease
facts and figures. Alzheimers Dement 10, e47-e92.
[2] Perl DP (2010) Neuropathology of Alzheimer’s disease. Mt
Sinai J Med 77, 32-42.
86 J.A. Snir et al. / Imaging Cathepsin D in Alzheimer’s Disease
[3] Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R,
Hill R, Hansen LA, Katzman R (1991) Physical basis of
cognitive alterations in Alzheimer’s disease: Synapse loss is
the major correlate of cognitive impairment. Ann Neurol 30,
572-580.
[4] Maruszak A, Zekanowski C (2011) Mitochondrial dysfunc-
tion and Alzheimer’s disease. Prog Neuropsychopharmacol
Biol Psychiatry 35, 320-330.
[5] Zlokovic BV (2011) Neurovascular pathways to neurodegen-
eration in Alzheimer’s disease and other disorders. Nat Rev
Neurosci 12, 723-738.
[6] Storkebaum E, Quaegebeur A, Vikkula M, Carmeliet P (2011)
Cerebrovascular disorders: Molecular insights and therapeu-
tic opportunities. Nat Neurosci 14, 1390-1397.
[7] Cummings J, Zhong K (2014) Biomarker-driven therapeutic
management of Alzheimer’s disease: Establishing the foun-
dations. Clin Pharmacol Ther 95, 67-77.
[8] Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B (2009)
Biomarkers in Alzheimer’s disease: Not yet surrogate end-
points. Ann N Acad Sci 1180, 119-124.
[9] Schneider LS, Mangialasche F, Andreasen N, Feldman H,
Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad
B, Kivipelto M (2014) Clinical trials and late-stage drug
development for Alzheimer’s disease: An appraisal from 1984
to 2014. J Intern Med 275, 251-283.
[10] Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s dis-
ease drug-development pipeline: Few candidates, frequent
failures. Alzheimers Res Ther 6, 37.
[11] Berk C, Sabbagh MN (2013) Successes and failures for drugs
in late-stage development for Alzheimer’s disease. Drugs
Aging 30, 783-792.
[12] Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC,
Quinn JF, Kaye JA (2008) Trajectories of brain loss in aging
and the development of cognitive impairment. Neurology 70,
828-883.
[13] Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC,
Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of
cerebral hypoperfusion in Alzheimer disease and mild cog-
nitive impairment measured with arterial spin-labeling MR
imaging: Initial experience. Radiology 234, 851-859.
[14] Borroni B, Anchisi D, Paghera B, Vicini B, Kerrouche N,
Garibotto V, Terzi A, Vignolo LA, Di Luca M, Giubbini R,
Padovani A, Perani D (2006) Combined 99mTc-ECD SPECT
and neuropsychological studies in MCI for the assessment of
conversion to AD. Neurobiol Aging 27, 24-31.
[15] Dickerson BC, Sperling RA (2008) Functional abnormalities
of the medial temporal lobe memory system in mild cognitive
impairment and Alzheimer’s disease: Insights from functional
MRI studies. Neuropsychologia 46, 1624-1635.
[16] Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de
la Sayette V, Desgranges B, Baron JC (2005) Using voxel-
based morphometry to map the structural changes associated
with rapid conversion in MCI: A longitudinal MRI study.
Neuroimage 27, 934-946.
[17] Moulin CJ, Laine M, Rinne JO, Kaasinen V, Sipila H, Hiltunen
J, Kangasmaki A (2007) Brain function during multi-trial
learning in mild cognitive impairment: A PET activation
study. Brain Res 1136, 132-141.
[18] Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML,
Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-
substituted 2-arylbenzothiazoles as amyloid imaging agents.
J Med Chem 46, 2740-2754.
[19] Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman
T, Fox NC, Rossor MN (2006) Amyloid load and cerebral
atrophy in Alzheimer’s disease: An 11C-PiB positron emis-
sion tomography study. Ann Neurol 60, 145-147.
[20] Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G,
Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S,
Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti
BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B
(2004) Imaging brain amyloid in Alzheimer’s disease with
Pittsburgh Compound-B. Ann Neurol 55, 306-319.
[21] Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G,
Wall A, Ringheim A, Langstrom B, Nordberg A (2008) PET
imaging of amyloid deposition in patients with mild cognitive
impairment. Neurobiol Aging 29, 1456-1465.
[22] Jack J C R, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ,
Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis
CA, Petersen RC (2008) 11C PiB and structural MRI pro-
vide complementary information in imaging of Alzheimer’s
disease and amnestic mild cognitive impairment. Brain 131,
665-680.
[23] Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y
(2014) Tau PET imaging in Alzheimer’s disease. Curr Neurol
Neurosci Rep 14, 500.
[24] Zimmer ER, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P
(2014) In vivo tracking of tau pathology using positron emis-
sion tomography (PET) molecular imaging in small animals.
Transl Neurodegener 3, 6.
[25] Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X,
Desmond TJ, Sherman P, Quesada CA, Hockley BG, Kilbourn
MR, Albin RL, Frey KA, Scott PJ (2014) High affinity radio-
pharmaceuticals based upon lansoprazole for PET imaging
of aggregated tau in Alzheimer’s disease and progressive
supranuclear palsy: Synthesis, preclinical evaluation, and lead
selection. ACS Chem Neurosci 5, 718-730.
[26] Tago T, Furumoto S, Okamura N, Harada R, Ishikawa Y, Arai
H, Yanai K, Iwata R, Kudo Y (2014) Synthesis and prelimi-
nary evaluation of 2-arylhydroxyquinoline derivatives for tau
imaging. J Label. Comp Radiopharm 57, 18-24.
[27] Ossenkoppele R, Schonhaut DR, Baker SL, O’Neil JP, Janabi
M, Ghosh PM, Santos M, Miller ZA, Bettcher BM, Gorno-
Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2015)
Tau, amyloid, and hypometabolism in a patient with posterior
cortical atrophy. Ann Neurol 77, 338-342.
[28] Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C,
Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC (2014)
Early clinical PET imaging results with the novel PHF-tau
radioligand [F18]-T808. J Alzheimers Dis 38, 171-184.
[29] Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA,
Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR,
Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM,
Klunk WE (2008) Frequent amyloid deposition without sig-
nificant cognitive impairment among the elderly. Arch Neurol
65, 1509-1517.
[30] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A,
Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman
DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS,
Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL,
Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling
RA, Salloway S, Morris JC (2012) Clinical and biomarker
changes in dominantly inherited Alzheimer’s disease. N Engl
J Med 367, 795-804.
[31] Benes P, Vetvicka V, Fusek M (2008) Cathepsin D–many
functions of one aspartic protease. Crit Rev Oncol Hematol
68, 12-28.
[32] Cataldo AM, Paskevich PA, Kominami E, Nixon RA (1991)
Lysosomal hydrolases of different classes are abnormally
J.A. Snir et al. / Imaging Cathepsin D in Alzheimer’s Disease 87
distributed in brains of patients with Alzheimer disease. Proc
Natl Acad Sci U S A 88, 10998-11002.
[33] Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S,
Bursztajn S, Lippa C, Nixon RA (1995) Gene expression and
cellular content of cathepsin D in Alzheimer’s disease brain:
Evidence for early up-regulation of the endosomal-lysosomal
system. Neuron 14, 671-680.
[34] Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall
NW, Nixon RA (1995) Elevated levels of the endosomal-
lysosomal proteinase cathepsin D in cerebrospinal fluid in
Alzheimer disease. J Neurochem 64, 443-446.
[35] De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012)
Alzheimer’s disease. Subcell Biochem 65, 329-352.
[36] Strome EM, Doudet DJ (2007) Animal models of neurode-
generative disease: Insights from in vivo imaging studies. Mol
Imaging Biol 9, 186-195.
[37] Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron
JC, Chavoix C (1999) Neocortical and hippocampal glucose
hypometabolism following neurotoxic lesions of the entorhi-
nal and perirhinal cortices in the non-human primate as shown
by PET. Implications for Alzheimer’s disease. Brain 122
(Pt 8), 1519-1531.
[38] Millien I, Blaizot X, Giffard C, Mezenge F, Insausti R, Baron
JC, Chavoix C (2002) Brain glucose hypometabolism after
perirhinal lesions in baboons: Implications for Alzheimer dis-
ease and aging. J Cereb Blood Flow Metab 22, 1248-1261.
[39] Bhagat YA, Obenaus A, Richardson JS, Kendall EJ (2002)
Evolution of beta-amyloid induced neuropathology: Mag-
netic resonance imaging and anatomical comparisons in the
rodent hippocampus. MAGMA 14, 223-232.
[40] Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J,
Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik
L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid
aggregates, neurodegeneration, and neuron loss in transgenic
mice with five familial Alzheimer’s disease mutations: Poten-
tial factors in amyloid plaque formation. J Neurosci 26,
10129-10140.
[41] Kimura R, Ohno M (2009) Impairments in remote memory
stabilization precede hippocampal synaptic and cognitive fail-
ures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33,
229-235.
[42] Youmans KL, Tai LM, Kanekiyo T, Stine J, Michon WB,
Nwabuisi-Heath SC, Manelli E, Fu AM, Riordan Y, Eimer S,
Binder WA, Bu L, Yu G, Hartley C, LaDu DM, MJ (2012)
Intraneuronal Abeta detection in 5xFAD mice by a new Abeta-
specific antibody. Mol Neurodegener 7, 8.
[43] Amritraj A, Hawkes C, Phinney AL, Mount HT, Scott CD,
Westaway D, Kar S (2009) Altered levels and distribution of
IGF-II/M6P receptor and lysosomal enzymes in mutant APP
and APP+PS1 transgenic mouse brains. Neurobiol Aging 30,
54-70.
[44] Oldendorf WH (1971) Brain uptake of radiolabeled amino
acids, amines, and hexoses after arterial injection. Am J Phys-
iol 221, 1629-1639.
[45] Oldendorf WH (1974) Lipid solubility and drug penetra-
tion of the blood brain barrier. Proc Soc Exp Biol Med 147,
813-815.
[46] Penichet ML, Kang YS, Pardridge WM, Morrison SL, Shin
SU (1999) An antibody-avidin fusion protein specific for the
transferrin receptor serves as a delivery vehicle for effective
brain targeting: Initial applications in anti-HIV antisense drug
delivery to the brain. J Immunol 163, 4421-4426.
[47] Banks WA (2009) Characteristics of compounds that cross
the blood-brain barrier. BMC Neurol 9 Suppl 1, S3.
[48] Banks WA, Robinson SM, Nath A (2005) Permeability of the
blood-brain barrier to HIV-1 Tat. Exp Neurol 193, 218-227.
[49] Temsamani J, Vidal P (2004) The use of cell-penetrating pep-
tides for drug delivery. Drug Discov Today 9, 1012-1019.
[50] Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms
D (2009) An improved cell-penetrating, caspase-activatable,
near-infrared fluorescent peptide for apoptosis imaging. Bio-
conjug Chem 20, 702-709.
[51] Madani F, Lindberg S, Langel U, Futaki S, Graslund A (2011)
Mechanisms of cellular uptake of cell-penetrating peptides.
J Biophy 2011, 414729.
[52] Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait
MJ, Chernomordik LV, Lebleu B (2003) Cell-penetrating pep-
tides. A reevaluation of the mechanism of cellular uptake.
J Biol Chem 278, 585-590.
[53] Mishra R, Su W, Pohmann R, Pfeuffer J, Sauer MG, Ugurbil
K, Engelmann J (2009) Cell-penetrating peptides and pep-
tide nucleic acid-coupled MRI contrast agents: Evaluation
of cellular delivery and target binding. Bioconjug Chem 20,
1860-1868.
[54] Suchy M, Ta R, Li AX, Wojciechowski F, Pasternak SH,
Bartha R, Hudson RH (2010) A paramagnetic chemical
exchange-based MRI probe metabolized by cathepsin D:
Design, synthesis and cellular uptake studies. Org Biomol
Chem 8, 2560-2566.
[55] Ta R, Suchy M, Tam JH, Li AX, Martinez-Santiesteban FS,
Scholl TJ, Hudson RH, Bartha R, Pasternak SH (2013) A
dual magnetic resonance imaging/fluorescent contrast agent
for Cathepsin-D detection. Contrast Media Mol Imaging 8,
127-139.
[56] Kovar JL, Simpson MA, Schutz-Geschwender A, Olive DM
(2007) A systematic approach to the development of fluo-
rescent contrast agents for optical imaging of mouse cancer
models. Anal Biochem 367, 1-12.
[57] Robinson HA, Kwon S, Hall MA, Rasmussen JC, Aldrich
MB, Sevick-Muraca EM (2013) Non-invasive optical imaging
of the lymphatic vasculature of a mouse. J Vis Exp, e4326.
[58] Sampath L, Wang W, Sevick-Muraca EM (2008) Near
infrared fluorescent optical imaging for nodal staging.
J Biomed Opt 13, 041312.
[59] Marshall MV, Draney D, Sevick-Muraca EM, Olive DM.
(2010) Single-dose intravenous toxicity study of IRDye
800CW in Sprague-Dawley rats. Mol Imaging Biol 12,
583-594.
[60] Kovar JL, Xu X, Draney D, Cupp A, Simpson MA, Olive
DM (2011) Near-infrared-labeled tetracycline derivative is an
effective marker of bone deposition in mice. Anal Biochem
416, 167-173.
[61] Coin I, Beyermann M, Bienert M (2007) Solid-phase pep-
tide synthesis: From standard procedures to the synthesis of
difficult sequences. Nat Protoc 2, 3247-3256.
[62] Sarko D, Beijer B, Garcia Boy R, Nothelfer EM, Leotta K,
Eisenhut M, Altmann A, Haberkorn U, Mier W (2010) The
pharmacokinetics of cell-penetrating peptides. Mol Pharm 7,
2224-2231.
[63] Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME,
Sevick-Muraca EM (2007) Dual-labeled trastuzumab-based
imaging agent for the detection of human epidermal growth
factor receptor 2 overexpression in breast cancer. J Nucl Med
48, 1501-1510.
